Chongqing Taiji Industry Group Co Ltd
SSE:600129
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
C
|
Chongqing Taiji Industry Group Co Ltd
SSE:600129
|
10B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Chongqing Taiji Industry Group Co Ltd
Glance View
Amidst the sprawling urban landscape of Chongqing, a city often enveloped in a mystical cloak of fog, stands Chongqing Taiji Industry Group Co Ltd., a distinguished entity in the realm of pharmaceuticals. Commanding a legacy that spans over a century, Taiji Industry has mastered the delicate fusion of traditional Chinese medicine with modern pharmaceutical processes. This synthesis has propelled the company to the forefront of China's healthcare sector. The company’s operations revolve around robust research and development, manufacturing, and distribution, focusing on a diverse array of pharmaceutical products, health supplements, and TCM (Traditional Chinese Medicine) remedies. Seamlessly integrating innovation with traditional wisdom, the group has built an extensive portfolio catering to a wide range of medical needs, from cardiovascular treatments to neurological supports. Financially, Taiji Industry's prowess is underpinned by its diverse revenue streams, primarily flowing from its broad spectrum of medicinal drugs and health products. The company has capitalized on its established brand and extensive distribution networks, which span across the vast Chinese landscape and extend their reach into international markets. Their stronghold in distribution is further solidified by strategic collaborations with healthcare providers and retail pharmacy chains, ensuring reliable market penetration and accessibility to the end consumer. This well-oiled machine not only secures Taiji's position as a major pharmaceutical player but also drives its financial growth, allowing the company to invest continuously in innovation, quality enhancement, and market expansion. The synergistic blend of tradition and modernity continues to propel Taiji Industry through the ever-evolving pharmaceutical landscape.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Chongqing Taiji Industry Group Co Ltd is -3.5%, which is below its 3-year median of 2.4%.
Over the last 3 years, Chongqing Taiji Industry Group Co Ltd’s Net Margin has increased from -4% to -3.5%. During this period, it reached a low of -4% on Aug 30, 2022 and a high of 5.5% on Sep 30, 2023.